U.S. FDA approves TREMFYA ® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's

21 hours ago 1

1. Homepage
2. Personal Finance
3. U.S. FDA approves TREMFYA ® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's